Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kaiser FluMist Safety Data Analysis To Be Submitted To FDA By Year-End

Executive Summary

Aviron expects to submit to FDA the full analysis of a FluMist pediatric safety study conducted at Kaiser Permanente outpatient clinics by the end of the year.
Advertisement

Related Content

FluMist Initial Indication May Exclude Patients Under Age Five
FluMist Initial Indication May Exclude Patients Under Age Five
Medimmune FluMist Indication Could Exclude Patients With Asthma
Medimmune FluMist Indication Could Exclude Patients With Asthma
Aviron FluMist Annual Release Tests In Human Subjects May Be Required
Aviron FluMist Annual Release Tests In Human Subjects May Be Required
Aviron FluMist Annual Release Tests In Human Subjects May Be Required
Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.
Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.
Advertisement
UsernamePublicRestriction

Register

PS038301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel